Diagnostic biomarkers for pancreatic cancer: An update |
| |
Authors: | Ming Yang Chun-Ye Zhang |
| |
Affiliation: | Ming Yang, Department of Surgery, University of Missouri, Columbia, MO 65212, United StatesChun-Ye Zhang, Department of Veterinary Pathobiology, University of Missouri, Columbia, MO 65212, United States |
| |
Abstract: | Pancreatic ductal adenocarcinoma accounts for the primary type of pancreatic cancer (PC) with a 5-year survival rate of only about 10% in the United States. Early diagnosis will improve chances for curative treatment. To date, a broadly used serum marker for PC diagnosis is carbohydrate antigen 19-9, which is the only approved biomarker currently by the United States Food and Drug Administration. However, it has low specificity; therefore, development of novel biomarkers is urgently needed. Clinical trials are ongoing to evaluate candidate biomarkers for PC diagnosis, and the use of a multi-biomarker panel with current PC diagnostic biomarkers appears promising. |
| |
Keywords: | Pancreatic ductal adenocarcinoma Diagnosis Biomarkers Panel Clinical trials |
|
| 点击此处可从《World journal of gastroenterology : WJG》浏览原始摘要信息 |
|